Liliana Baila

TL;DR: In this article, the authors compared low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy.

TL;DR: In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubic in enhances the long-term efficacy of chemotherapy.

TL;DR: The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were not considered eligible for conventional chemotherapy because of advanced age or poor performance status as mentioned in this paper.

TL;DR: An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence, suggesting that prophylactic cranial irradiation can safely be omitted.

TL;DR: A randomized phase III study comparing low dose Decitabine to supportive care in patients of 60 years or older with primary or secondary MDS or CMML and found toxicity was mainly cytopenia related toxicity that was either disease related or hematotoxicity.